November marks Lung Cancer Awareness Month, and BioMark Diagnostics Inc. (CNSX: BUX) (FSE: 20B) (OTCQB: BMKDF) is demonstrating its role in advancing early detection of lung cancer across Canada.
The company is supporting the Canadian Cancer Society’s 2026-2035 Pan-Canadian Lung Cancer Action Plan, which aims to reduce lung cancer mortality by 30 per cent over the next decade.
BioMark, a developer of AI powered liquid biopsy technologies, focuses on identifying cancer in its earliest stages. The company said its approach aligns closely with the Action Plan’s goals of saving lives through early detection.
“Providing fair, evidence based access to early lung cancer testing can dramatically improve outcomes for Canadians,” said Rashid Bux, CEO and President of BioMark.
He noted that the company’s clinical results show its biomarker tests can detect early stage cancers, including in non-smokers, complementing existing low dose CT screenings.
In addition, BioMark showed the importance of expanding access to underserved and remote communities. Blood-based biomarker testing, the company explained, can improve diagnostic accuracy and increase early-stage detection rates. The company also expressed interest in working with provincial healthcare providers, national partners, and community organizations.
The Pan-Canadian Lung Cancer Action Plan emphasizes prevention, early detection, treatment, and support. It calls for innovative diagnostic tools and methods, including blood based tests, to help Canadians access timely care. Consequently, national collaboration and new technologies are critical to reaching the plan’s ambitious targets.
Read more: Breath Diagnostics leaders promote their mission at Miami investment conference
Read more: Breath Diagnostics leader speaks at lung cancer education event in Louisville
Cancer detection technology has been advancing
There are a growing number of technologies working to detect lung cancer early, including established public companies and innovative startups.
For example, GRAIL, Inc. (NASDAQ: GRAL) offers its “Galleri” multi cancer early detection blood test, which uses methylation sequencing and artificial intelligence to find a range of cancers from a small sample of blood.
Meanwhile, Exact Sciences Corporation (NASDAQ: EXAS) has launched its Cancerguard blood test, designed to detect over 50 types of cancer including lung cancer by analyzing multiple biomarker classes in a blood sample.
On the startup side, Breath Diagnostics, Inc. is developing a non-invasive breath-analysis system called OneBreath. This tech captures volatile organic compounds in a single exhaled breath and reports high sensitivity and specificity for lung cancer detection.
Similarly, Dxcover Limited is using liquid-biopsy and spectral analysis to detect multiple cancers from simple blood samples. It’s also using artificial intelligence to interpret the results.
In addition to conventional imaging such as low-dose CT scans, these newer methods offer broader screening potential, earlier detection in non-smokers, and less invasive testing. They also still face challenges in real-world uptake, reimbursement, and clinical validation.
